Press Release Archive

April 21, 2011 - Pfizer Comments on ORAL Sync Tofacitinib Data in EULAR Abstract LB0005

(BUSINESS WIRE)--Pfizer Inc. commented on an abstract concerning the ORAL Sync Phase 3 study of tofacitinib in patients with rheumatoid arthritis (RA) which has been posted for the European League Against Rheumatism (EULAR) conference. In this study, four deaths were reported in the tofacitinib arms, three of which were determined by the investigators not to be study drug related. The cases reported that were determined not to be

April 21, 2011 - Pfizer Invites Public To Listen To Webcast Of April 28 Annual Meeting Of Shareholders

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Central Daylight Time) on Thursday, April 28. To access the Webcast, visit our Web site at www.pfizer.com/annualmeeting and click on the “Annual Meeting of Shareholders Webcast” link. Information on accessing and pre-registering for the Webcast will be available at www.pfizer.com beginning

April 20, 2011 - Pfizer and Shanghai Pharmaceutical Sign Memorandum of Understanding for Potential Strategic Partnership

(BUSINESS WIRE)--Shanghai Pharmaceutical Co. Ltd. (SHSE: 601607) and Pfizer Inc. (NYSE: PFE) today announced the signing of a memorandum of understanding (MOU) for the companies to jointly pursue potential business opportunities in China. The potential partnership is intended to leverage both companies’ strengths, matching Pfizer’s global capabilities in developing innovative medicines with Shanghai Pharmaceutical

April 14, 2011 - Pfizer Announces Top-Line Results Of Third Phase 3 Clinical Trial Of Tofacitinib (CP-690,550) In Patients With Active Rheumatoid Arthritis

(BUSINESS WIRE)--Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study (A3921044) of tofacitinib (development code: CP-690,550), formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor. ORAL Scan is an ongoing two-year study in patients with moderate-to-severe active rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX) and were randomized to receive tofacitinib 5 or 10 mg

April 12, 2011 - Tafamidis, An Oral, Investigational Compound For The Treatment Of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) Sustained A Slowing Of Disease Progression Over 30 Months

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today data from an open-label extension study (Fx-006) of the pivotal Phase II/III (Fx-005) trial. This extension study evaluated the long-term clinical outcomes of tafamidis, a novel, oral, investigational compound being studied as a treatment for patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP). TTR-FAP is a rare and fatal neurodegenerative disease affecting

April 12, 2011 - FDA Advisory Committee Finds Data Support The Favorable Benefit-Risk Profile Of SUTENT® In Unresectable Pancreatic Neuroendocrine Tumors (NET)

(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. FDA Oncologic Drugs Advisory Committee (ODAC) voted 8-2 that SUTENT® (sunitinib malate) provides a favorable benefit-risk profile for the treatment of unresectable pancreatic neuroendocrine tumors (NET). The panel’s advice will be considered by the FDA when finalizing its review of Pfizer’s supplemental New Drug Application (sNDA) for sunitinib for this indication. "We

April 10, 2011 - Pfizer and Medivation Announce Results from Phase 3 HORIZON Trial of Dimebon in Huntington Disease

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced results from the Phase 3 HORIZON trial of the investigational drug dimebon (latrepirdine*) in patients with Huntington disease. Dimebon did not achieve statistical significance for either of the co-primary endpoints, the Mini-Mental State Examination (MMSE), which measures cognition (p=0.39), or the Clinician's Interview-Based

April 5, 2011 - Pfizer Invites Public To View And Listen To Webcast Of May 3 Conference Call With Analysts

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 3, 2011. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2011 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web

April 3, 2011 - Pfizer Receives Refusal To File Letter From U.S. FDA On Tafamidis New Drug Application

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) for tafamidis, the company’s novel, oral investigational compound for patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP). Upon preliminary review, the FDA determined that the application, which was submitted in February 2011, was not sufficiently complete to

April 3, 2011 - Pfizer to Sell Capsugel to KKR

(BUSINESS WIRE)--Pfizer and Kohlberg Kravis Roberts & Co L.P. (together with its affiliates, “KKR”) today announced they have entered into an agreement whereby an affiliate of KKR will acquire Pfizer’s Capsugel business for $2.375 billion in cash. Capsugel, the world leader in hard capsules and an innovator in drug-delivery systems, generated approximately $750 million in revenue and manufactured more than 180 billion hard capsules

March 31, 2011 - Pfizer Oncology To Present Broad Array Of New Pre-Clinical And Clinical Data From Early And Late Stage Compounds

(BUSINESS WIRE)--Pfizer Oncology will present nearly 30 abstracts highlighting research in new and established pathways, including inhibition of Hedgehog signaling (PF-04449913);1 dual inhibition of PI3K/mTOR (phosphatidylinositol 3-kinase/mammalian target of rapamycin)(PF-04691502);2 and cancer stem cell-based targets.3 Data from this research as well as data from studies involving investigational compounds, including crizotinib,4 an ora

March 31, 2011 - Pfizer Posts Details Of Interactions With U.S. Health Care Professionals And Researchers In 2010

(BUSINESS WIRE)--Pfizer Inc. today released a report detailing the company’s financial interactions with health care professionals and researchers in 2010. Specifically, the report, posted today on www.pfizer.com/WorkingWithHCP, presents 2010 data on payments -- including compensation for clinical research activities, professional consulting, and speaking at expert-led forums –- and the value of other items, such as meals, educational items

March 26, 2011 - Greenstone Announces Voluntary Nationwide Recall of Citalopram and Finasteride Due to Possible Mislabeling

(BUSINESS WIRE)--Greenstone LLC announced today that it is voluntarily conducting a recall, to the patient level, of medicines with lot number FI0510058-A on the label. This includes Citalopram 10mg Tablets (100-count bottle) and Finasteride 5mg Tablets (90-count bottle), both distributed in the U.S. market. The recall is due to the possibility that incorrect labels have been placed on the bottles by a third-party manufacturer. This is

March 24, 2011 - Pfizer Animal Health Continues to Invest in the Future of Veterinarians with Announcement of 2011 Veterinary Scholarship Recipients

(BUSINESS WIRE)--As part of its ongoing commitment to invest in the future of the veterinary profession, Pfizer Animal Health today announced the recipients of its second annual student scholarship program. Pfizer awarded $2,500 each to 300 second- and third-year veterinary students at accredited universities throughout the United States and the Caribbean, for a total of $750,000. A total of 1,562 students applied for the

March 23, 2011 - SPIRIVA HandiHaler Prolonged Time To First COPD Exacerbation, New Study In NEJM Shows

(BUSINESS WIRE)--RIDGEFIELD, Conn.

March 9, 2011 - Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Barclays Capital 2011 Global Healthcare Conference on Thursday, March 17, 2011 at 11:15 a.m. Eastern Daylight Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Barclays Capital 2011 Global

March 3, 2011 - Pfizer Announces Primary Endpoints Met In Second Phase 3 Clinical Trial Of Tofacitinib (CP-690,550) In Patients With Active Rheumatoid Arthritis

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the ORAL Sync Phase 3 study (A3921046) of tofacitinib (development code: CP-690,550), formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis (RA), met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates

March 1, 2011 - World-Class Professional Golfer Phil Mickelson Launches “On Course with Phil” for People with Certain Inflammatory Joint and Skin Conditions

(BUSINESS WIRE)--THOUSAND OAKS, Calif.,

March 1, 2011 - King Pharmaceuticals, Inc. Announces Final Results of Its Offer to Purchase Convertible Notes

(BUSINESS WIRE)--King Pharmaceuticals, Inc. (the “Company”), a wholly owned subsidiary of Pfizer Inc., announced today the final results of its tender offer to purchase (the “Fundamental Change Put Option”) any and all of its outstanding 1 1/4% Convertible Senior Notes Due 2026 (the “Securities”). The Fundamental Change Put Option expired on February 28, 2011, at 11:59 p.m., New York City time (the “Expiration Date”). The

February 28, 2011 - Pfizer Completes Acquisition Of King Pharmaceuticals, Inc.

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it has combined operations with King Pharmaceuticals, Inc. On February 28, 2011, Pfizer completed its acquisition of King through the merger of its wholly owned subsidiary, Parker Tennessee Corp., with and into King. King is now a wholly owned subsidiary of Pfizer. Under the terms of the transaction, each outstanding share of King common stock has been converted into the right to

Press release archive foot note

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

Stay on top of Pfizer breaking news: Get News Alerts by RSS.

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

If you do not have Adobe^® Reader, download it here. It is available without charge from Adobe^®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.